ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378
Ru
En

Assessment of Thyroid Function and Metabolic Disorders in Management of Prostate Cancer with Agonists of LH Releasing Hormone

DOI:10.31550/1727-2378-2020-19-2-56-62
Bibliography link: Gritskevich E.Yu., Demidova T.Yu., Maturov M.R., Bystrov A.A., Gritskevich A.A., Neudakhina V.O. Assessment of Thyroid Function and Metabolic Disorders in Management of Prostate Cancer with Agonists of LH Releasing Hormone. Doctor.Ru. 2020; 19(2): 56–62. (in Russian) DOI: 10.31550/1727-2378-2020-19-2-56-62
Assessment of Thyroid Function and Metabolic Disorders in Management of Prostate Cancer with Agonists of LH Releasing Hormone
22 April 10:28

Study Objective: to assess thyroid function and metabolic disorders in patients with local prostate cancer (pT3N0M0) or biochemical relapse after total prostatectomy for local prostate cancer, who were treated with agonists of luteinizing hormone-releasing hormone (aLHRH).

Study Design: follow-up study.

Materials and Methods. 102 patients were enrolled to the study, 99 subjects were followed up till the study completion. The mean age was 69 years old (95% confidence range: 61.5-79.2 years old). To assess thyroid function, thyroid-stimulating hormone (TSH) and free T4 were measured prior to and in 12 months after androgen depriving therapy (ADT). To see metabolic disorders, waist circumference (WC), body mass index (BMI), and total cholesterol (TH) were measured prior to and 3, 6 and 12 months after ADT initiation.

Study Results. The following changes were noted in test parameters: thyroid hormones (basic and 12 months later, respectively): TSH (mU/L): 1.67506 and 1.90684 (p < 0.001), free T4 — 11.6266 and 11.0555 (p < 0.001). Metabolic parameters (basic, 3, 6 and 12 months, respectively): WC (cm): 91.5, 95.4 (+4.2%), 96.1 (+5.0%), 96.4 (+5.4%) (for all differences p ≤ 0.017); BMI (kg/m2): 27.4, 28.2 (+2.9%), 28.4 (+3.6%), 28.4 (+3.6%) (p ≤ 0.004 for all differences, save for differences between values in 6 and 12 months — p = 0.995); TC (mmol/L): 5.2, 5.6 (+7.7%), 5.8 (+11.5%), 5.9 (+13.5%) (for all differences p ≤ 0.001). Statistically significant positive correlation was recorded between TSH and TC dynamics (R = 0.285, p = 0.004), statistically significant negative correlation — between TSH and free T4 (R = –0.315, p = 0.001).

Conclusion. aLHRH monotherapy led to the trend of increase in WC, body mass, TSH raise and free T4 reduction one year after ADT, though mean hormone values were within acceptable range; TH demonstrated an increase. The highest increase in WC, BMI, TH was recorded within first 3 months of therapy, then the rate of increase diminished. Further study of metabolic and hormonal complications from ADT and evidence base enhancement are required in order to check the data and develop measures to prevent complications.

Contribution: Gritskevich, E.Yu. — subjects selection, sampling, thematic publications reviewing, statistical processing, data analysis and interpretation, manuscript preparation; Demidova, T.Yu. — study design, review of critically important material, approval of the manuscript for publication; Maturov, M.R., Bystrov, A.A. — subjects selection, database generation; Gritskevich, A.A. — participation in manuscript preparation, article reviewing; Neudakhina, V.O. — partial data analysis, participation in manuscript preparation.

Conflict of interest: The authors declare that they do not have any conflict of interests.

E.Yu. Gritskevich (Corresponding author) — N.I. Pirogov Russian National Research Medical University (a Federal State Autonomous Educational Institution of Higher Education), Russian Ministry of Health; 4 Shkulev St., Bldg. 1, Moscow, Russian Federation 109263. eLIBRARY.RU SPIN: 4125-2055. ORCID: https://orcid.org/0000-0002-0086-869X. E-mail: genyan.7@mail.ru

T.Yu. Demidova — N.I. Pirogov Russian National Research Medical University (a Federal State Autonomous Educational Institution of Higher Education), Russian Ministry of Health; 4 Shkulev St., Bldg. 1, Moscow, Russian Federation 109263. eLIBRARY.RU SPIN: 9600-9796. ORCID: https://orcid.org/0000-0001-6385-540X. Scopus Author ID: 7003771623. E-mail: t.y.demidova@gmail.com

M.R. Maturov — Outpatient Cancer Care Centre at Pletnev Municipal Clinical Hospital at Moscow Healthcare Department; 29 Verkhyaya Pervomayskaya, Moscow, Russian Federation 105264. E-mail: mihail.maturov@yandex.ru

A.A. Bystrov — Moscow Municipal Oncology Hospital No.62 of Moscow Healthcare Department (outpatient unit); 6/2 Staropetrovskiy Proezd, Moscow, Russian Federation 125130. Е-mail: bystrov@list.ru

A.A. Gritskevich — Vishnevskiy National Medical Scientific Centre of Surgery of the Ministry of Health of the Russian Federation; 27 Bolshaya Serpukhovskaya Str., Moscow, Russian Federation 117997. eLIBRARY.RU SPIN: 2128-7536. ORCID: https://orcid.org/0000-0002-5160-925X. Е-mail: grekaa@mail.ru

V.O. Neudakhina — N.I. Pirogov Russian National Research Medical University (a Federal State Autonomous Educational Institution of Higher Education), Russian Ministry of Health; 4 Shkulev St., Bldg. 1, Moscow, Russian Federation 109263. ORCID: https://orcid.org/0000-0003-0809-0429. E-mail: NeudakhinaVeronika@yandex.ru

Table 1
Dynamics of mean thyroid-stimulating hormone (TSH) and free T4 values

t9_1.jpg

Fig. 1. Dynamics of mean thyroid-stimulating hormone (TSH) values

r9_1.jpg

Fig. 2. Dynamics of free T4 values

r9_2.jpg

Table 2
Comparison of thyroid-stimulating hormone and free T4 prior to and 12 months after hormone therapy initiation (t-test for paired samples)

t9_2.jpg

Table 3
Dynamics of mean body mass index (BMI), kg/m2

t9_3.jpg

* Statistically significant differences from basic parameter (p ≤ 0.004).

Fig. 3. Diagram of changes in mean body mass index (BMI) over time.

* Statistically significant differences from basic parameter (p ≤ 0.004)

r9_3.jpg

Table 4
Dynamics of mean waist circumference (WC) value, cm

t9_4.jpg

* Statistically significant differences from basic parameter (p ≤ 0,017).

Fig. 4. Diagram of changes in mean waist circumference (WC) over time.

* Statistically significant differences from basic parameter (p ≤ 0.017)

r9_4.jpg

Table 5
Changes in mean total cholesterol (TC) over time, mmol/L

t9_5.jpg

* Statistically significant differences from basic parameter (p < 0,001). Fig. 5. Diagram of changes in mean total cholesterol (TC) over time.

* Statistically significant differences from basic parameter (p < 0.001)

r9_5.jpg

Table 6
Correlation of changes in thyroid-stimulating hormone (TSH) and free T4 values with other parameters

t9_6.jpg

Received: 18.02.2020
Accepted: 23.03.2020

Assessment of Thyroid Function and Metabolic Disorders in Management of Prostate Cancer with Agonists of LH Releasing Hormone
22 April 10:28
LITERATURE
  1. Ministry of Health of the Russian Federation. Clinical Recommendations. Prostate Cancer. 2018. (in Russian)
  2. Gamat M., McNeel D.G. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr. Relat. Cancer. 2017; 24(12): T297–310. DOI: 10.1530/ERC-17-0145
  3. Alferov S.M., Dariy E.V. Role of hormone therapy in the mortality rate of patients with prostate cancer. Kremlin Medicine. Clinical Bulletin. 2017; 1(4): 221–6. (in Russian)
  4. Nelson W.G. Commentary on Huggins and Hodges: “Studies on Prostatic Cancer”. Cancer Res. 2016; 76(2): 186–7. DOI: 10.1158/0008-5472.CAN-15-3172
  5. Zhang W., van Gent D.C., Incrocci L., van Weerden W.M., Nonnekens J. Role of the DNA damage response in prostate cancer formation, progression and treatment. Prostate Cancer Prostatic Dis. 2020; 23(1): 24–37. DOI: 10.1038/s41391-019-0153-2
  6. Mitsuzuka K., Arai Y. Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int. J. Urol. 2018; 25(1): 45–53. DOI: 10.1111/iju.13473
  7. Cheung A.S., Hoermann R., Dupuis P., Joon D.L., Zajac J.D., Grossmann M. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer. Eur. J. Endocrinol. 2016; 175(3): 229–37. DOI: 10.1530/EJE-16-0200
  8. Gritskevich A.A., Medvedev V.L., Mishugin S.V., Rusakov I.G. Metabolic status in patients with prostate cancer during different hormone therapy regimens. P.A. Herzen Journal of Oncology. 2014; 2(3): 26–30. (in Russian)
  9. Tzortzis V., Samarinas M., Zachos I., Oeconomou A., Pisters L.L., Bargiota A. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones (Athens). 2017; 16(2): 115–23. DOI: 10.14310/horm.2002.1727
  10. Mitsuzuka K., Kyan A., Sato T., Orikasa K., Miyazato M., Aoki H. et al. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Prostate Cancer Prostatic Dis. 2016; 19(1): 57–62. DOI: 10.1038/pcan.2015.50
  11. Lam T., Birzniece V., McLean M., Gurney H., Hayden A., Cheema B.S. The adverse effects of androgen deprivation therapy in prostate cancer and the benefits and potential anti-oncogenic mechanisms of progressive resistance training. Sports Med Open. 2020; 6(1): 13. DOI: 10.1186/s40798-020-0242-8
  12. Liu J.M., Yu C.P., Chuang H.C., Wu C.T., Hsu R.J. Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. Prostate Cancer Prostatic Dis. 2019; 22(3): 475–82. DOI: 10.1038/s41391-019-0130-9
  13. Tagliaferri V., Romualdi D., Guido M., Mancini A., De Cicco S., Di Florio C. et al. The link between metabolic features and TSH levels in polycystic ovary syndrome is modulated by the body weight: an euglycaemic-hyperinsulinaemic clamp study. Eur. J. Endocrinol. 2016; 175(5): 433–41. DOI: 10.1530/EJE-16-0358
  14. Wagner M.S., Wajner S.M., Maia A.L. The role of thyroid hormone in testicular development and function. J. Endocrinol. 2008; 199(3): 351–65. DOI: 10.1677/JOE-08-0218
  15. Wajner S.M., Wagner M.S., Maia A.L. Clinical implications of altered thyroid status in male testicular function. Arq. Bras. Endocrinol. Metabol. 2009; 53(8): 976–82. DOI: 10.1590/s0004-27302009000800011
  16. Salmine E., Koskinen A., Backman H., Nurmi M. Effect of adjuvant androgen deprivation on thyroid function tests in prostate cancer patients. Anticancer Drugs. 2004; 15(4): 351–6. DOI: 10.1097/00001813-200404000-00007
  17. Morote J., Esquena S., Orsola A., Salvador C., Trilla E., Cecchini L. et al. Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer. Anticancer Drugs. 2005; 16(8): 863–6. DOI: 10.1097/01.cad.0000173474.82486.74
  18. Hoermann R., Cheung A.S., Milne M., Grossmann M. hypothalamic-pituitary-thyroid axis set point alterations are associated with body composition in androgen-deprived men. J. Endocr. Soc. 2017; 1(7): 874–85. DOI: 10.1210/js.2017-00057
  19. Alexeev B.Ya., Nyushko K.M., Kaprin A.D. Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer. Medical Council. 2018; 19: 96–100. (in Russian). DOI: 10.21518/2079-701X-2018-19-96-100
Similar article
19 May 15:04, Allergology
V.M. Ganuzin, N.L. Chernaya, G.S. Maskova
Features of Specialised Medical Consultation of Adolescents with Bronchial Asthma: Clinical Observation
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)
19 May 14:30, Allergology
S.E. Mitskevich, I.A. Fedorov, A.I. Chuprynina, O.G. Rybakova
Use of Omalizumab in Management of Severe Uncontrolled Bronchial Asthma in Children
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)

Partners